Aardvark Therapeutics Shares Additional Details on Voluntary Pause of HERO Clinical Trial

Last month, we shared that Aardvark Therapeutics announced a voluntary pause in enrollment and dosing for the Phase 3 HERO clinical trial evaluating ARD-101 for hyperphagia in individuals with Prader-Willi syndrome (PWS). In a new update, Aardvark has provided additional details to help explain this decision and outline next steps. According to the announcement shared...

Important Update for the PWS Community: HERO Phase 3 Trial for ARD-101 Voluntarily Paused

We would like to share an important update from Aardvark Therapeutics. Aardvark has announced a voluntary pause of the Phase 3 HERO clinical trial, which is evaluating ARD‑101 for the treatment of hyperphagia in people with Prader‑Willi syndrome. The decision to pause the trial is based on reversible cardiac observations identified in a non-PWS, separate healthy...